{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T07:11:15Z","timestamp":1777965075813,"version":"3.51.4"},"reference-count":17,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2022,10,11]],"date-time":"2022-10-11T00:00:00Z","timestamp":1665446400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2022,10,11]],"date-time":"2022-10-11T00:00:00Z","timestamp":1665446400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Immunity Inflam &amp; Disease"],"published-print":{"date-parts":[[2022,11]]},"abstract":"Abstract<\/jats:title>\n \n Objective<\/jats:title>\n To explore the therapeutic effectiveness and safety of belimumab in the treatment of recently diagnosed systemic lupus erythematosus (SLE).<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n Between January 2019 and February 2022, a total of 30 patients who had been recently diagnosed with SLE were selected for 6 months of belimumab treatment at the Department of Rheumatology and Immunology, Tianjin First Central Hospital. Laboratory test results and related adverse reactions were recorded at baseline and after treatment.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Participants' white blood cell counts and complement 3, complement 4, and hemoglobin levels were higher after treatment than at baseline. Participants' immunoglobulin G and immunoglobulin M levels, SLE Disease Activity Index 2000 scores, glucocorticoid doses, erythrocyte sedimentation rates, and serum albumin\/globulin ratios were lower after treatment. These differences were all statistically significant (\n p<\/jats:italic>\n \u2009<\u2009.05).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n Belimumab was safe and effective in patients recently diagnosed with SLE and might help to reduce the use of glucocorticoids and to improve anemia with few adverse reactions. Belimumab might be applied in the treatment of patients recently diagnosed with SLE with high disease activity.<\/jats:p>\n <\/jats:sec>","DOI":"10.1002\/iid3.716","type":"journal-article","created":{"date-parts":[[2022,10,11]],"date-time":"2022-10-11T12:08:24Z","timestamp":1665490104000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Short\u2010term clinical observations of belimumab in the treatment of recently diagnosed systemic lupus erythematosus"],"prefix":"10.1002","volume":"10","author":[{"given":"Chunye","family":"Wu","sequence":"first","affiliation":[{"name":"Department of Immunology The Tianjin First Central Hospital Tianjin China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2388-3745","authenticated-orcid":false,"given":"Baoqi","family":"Gong","sequence":"additional","affiliation":[{"name":"Department of Immunology The Tianjin First Central Hospital Tianjin China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2022,10,11]]},"reference":[{"issue":"3","key":"e_1_2_7_2_1","first-page":"172","article-title":"Rheumatology branch of Chinese medical association, national clinical research center for skin and immune diseases, China SLE research collaborative group. 2020 Chinese guidelines for the diagnosis and treatment of systemic lupus erythematosus","volume":"59","year":"2020","journal-title":"Zhong Hua Nei Ke Za Zhi"},{"issue":"2","key":"e_1_2_7_3_1","first-page":"130","article-title":"Belimumab: A new targeted drug for systemic lupus erythematosus","volume":"11","author":"He CM","year":"2020","journal-title":"Union Medical Journal"},{"issue":"3","key":"e_1_2_7_4_1","first-page":"241","article-title":"New biologic targets for systemic lupus erythematosus: hope and challenge","volume":"11","author":"Yang HX","year":"2020","journal-title":"Union Medical Journal"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1177\/0961203319876998"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.41253"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.40930"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.40861"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-0872-z"},{"issue":"4","key":"e_1_2_7_10_1","first-page":"413","article-title":"Progress in the treatment of systemic lupus erythematosus in children with belizumab","volume":"20","author":"Shi Z","year":"2021","journal-title":"Chinese J\u00a0Integ\u00a0Dermatol\u00a0Venereol"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1177\/0961203319876998"},{"issue":"21","key":"e_1_2_7_12_1","first-page":"65","article-title":"System analysis of the efficacy and safety of belimumab in the treatment of systemic lupus erythematosus","volume":"34","author":"Wang J","year":"2021","journal-title":"J Med Inform"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S227208"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211631"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1177\/0961203320917748"},{"issue":"8","key":"e_1_2_7_16_1","first-page":"529","article-title":"Efficacy and safety of belimumab in the treatment of systemic lupus erythematosus","volume":"25","author":"Wang JR","year":"2021","journal-title":"Chinese J\u00a0Rheumatol"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1177\/0961203320981139"},{"issue":"50","key":"e_1_2_7_18_1","first-page":"3385","article-title":"A review on the treatment of systemic lupus erythematosus in children","volume":"10","author":"Huang X","year":"2021","journal-title":"Chong Qing Medicine"}],"container-title":["Immunity, Inflammation and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/iid3.716","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/iid3.716","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/iid3.716","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T07:13:52Z","timestamp":1773299632000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/iid3.716"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,11]]},"references-count":17,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["10.1002\/iid3.716"],"URL":"https:\/\/doi.org\/10.1002\/iid3.716","archive":["Portico"],"relation":{},"ISSN":["2050-4527","2050-4527"],"issn-type":[{"value":"2050-4527","type":"print"},{"value":"2050-4527","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,11]]},"assertion":[{"value":"2022-07-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-09-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-10-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e716"}}